The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Trends in development and approval times for new therapeutics in the United States
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era
Kaitin, K. I., & Healy, E. M. (2000) · Drug Information Journal · doi:10.1177/009286150003400101 · Cited by 45
Cited by
Designing hydrogels for controlled drug delivery
Li, J., & Mooney, D. J. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.71 · Cited by 4,832
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement
Lee, J. W., Devanarayan, V., Barrett, Y. C., Weiner, R., Allinson, J., Fountain, S., Keller, S., Weinryb, I., Green, M., Duan, L., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9045-3 · Cited by 768
Metadata
- Authors
- Reichert, J. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-09
- Volume
- 2
- Issue
- 9
- Pages
- 695-702
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1502809559
- Cited by
- 260
- References
- 2
- FWCI
- 47.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in development and approval times for new therapeutics in the United States. https://app.cochat.ai/papers/10.1038/nrd1178
- The paper
- Reichert, J. M. (2003). Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1178
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.